{"id":"NCT03508830","sponsor":"University of California, San Francisco","briefTitle":"Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial","officialTitle":"Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial - Liposomal Bupivacaine Versus Standard Bupivacaine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-30","primaryCompletion":"2021-01-30","completion":"2021-01-30","firstPosted":"2018-04-26","resultsPosted":"2021-06-08","lastUpdate":"2021-06-08"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Thoracic Diseases","Postoperative Pain","Opioid Use"],"interventions":[{"type":"DRUG","name":"Liposomal bupivacaine","otherNames":[]},{"type":"DRUG","name":"Bupivacaine Injection","otherNames":[]}],"arms":[{"label":"Liposomal Bupivacaine","type":"EXPERIMENTAL"},{"label":"Standard Bupivacaine","type":"ACTIVE_COMPARATOR"}],"summary":"The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.","primaryOutcome":{"measure":"Average Daily In-Hospital Use of Opioids","timeFrame":"Average over Entire Length of Hospitalization (Up to 1 Week)","effectByArm":[{"arm":"Liposomal Bupivacaine","deltaMin":40,"sd":28},{"arm":"Standard Bupivacaine","deltaMin":45,"sd":27}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":[]}}